BlackRock’s Adaptimmune Therapeutics ADAP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$42.9K Sell
179,087
-4,599
-3% -$1.1K ﹤0.01% 4946
2025
Q1
$36.2K Hold
183,686
﹤0.01% 4934
2024
Q4
$99K Sell
183,686
-99,940
-35% -$53.8K ﹤0.01% 4740
2024
Q3
$270K Buy
283,626
+89,869
+46% +$85.4K ﹤0.01% 4411
2024
Q2
$189K Sell
193,757
-95,931
-33% -$93.5K ﹤0.01% 4510
2024
Q1
$458K Buy
289,688
+110,107
+61% +$174K ﹤0.01% 4328
2023
Q4
$142K Sell
179,581
-1,086,543
-86% -$862K ﹤0.01% 4648
2023
Q3
$988K Buy
1,266,124
+103,996
+9% +$81.1K ﹤0.01% 4182
2023
Q2
$1.07M Buy
1,162,128
+278,161
+31% +$257K ﹤0.01% 4194
2023
Q1
$964K Sell
883,967
-89,022
-9% -$97K ﹤0.01% 4265
2022
Q4
$1.42M Sell
972,989
-441,258
-31% -$644K ﹤0.01% 4201
2022
Q3
$1.52M Buy
1,414,247
+47,340
+3% +$50.9K ﹤0.01% 4232
2022
Q2
$2.32M Buy
1,366,907
+36,068
+3% +$61.3K ﹤0.01% 4108
2022
Q1
$2.74M Buy
1,330,839
+160,146
+14% +$330K ﹤0.01% 4174
2021
Q4
$4.39M Sell
1,170,693
-90,179
-7% -$338K ﹤0.01% 3984
2021
Q3
$6.52M Buy
1,260,872
+279,478
+28% +$1.44M ﹤0.01% 3800
2021
Q2
$4.18M Sell
981,394
-512,952
-34% -$2.19M ﹤0.01% 3884
2021
Q1
$7.94M Buy
1,494,346
+39,472
+3% +$210K ﹤0.01% 3642
2020
Q4
$7.84M Buy
+1,454,874
New +$7.84M ﹤0.01% 3429
2019
Q4
Sell
-829,567
Closed -$1.25M 4910
2019
Q3
$1.25M Buy
829,567
+9,446
+1% +$14.3K ﹤0.01% 3848
2019
Q2
$3.3M Sell
820,121
-4,077
-0.5% -$16.4K ﹤0.01% 3589
2019
Q1
$3.54M Sell
824,198
-32,217
-4% -$139K ﹤0.01% 3491
2018
Q4
$4.92M Buy
856,415
+81,010
+10% +$466K ﹤0.01% 3377
2018
Q3
$10.5M Buy
775,405
+12,113
+2% +$164K ﹤0.01% 3189
2018
Q2
$9.06M Sell
763,292
-43,660
-5% -$518K ﹤0.01% 3252
2018
Q1
$9.06M Buy
806,952
+19,765
+3% +$222K ﹤0.01% 3145
2017
Q4
$5.26M Buy
787,187
+785,387
+43,633% +$5.25M ﹤0.01% 3382
2017
Q3
$15K Buy
+1,800
New +$15K ﹤0.01% 4567
2016
Q1
Sell
-600
Closed -$7K 3583
2015
Q4
$7K Buy
600
+430
+253% +$5.02K ﹤0.01% 2992
2015
Q3
$2K Hold
170
﹤0.01% 3133
2015
Q2
$3K Buy
+170
New +$3K ﹤0.01% 3135